These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6123078)

  • 1. [Intrinsic sympathomimetic activity with beta-receptor blockers. Significance for differential therapy (author's transl)].
    Noack E
    MMW Munch Med Wochenschr; 1982 Apr; 124(15):377-80. PubMed ID: 6123078
    [No Abstract]   [Full Text] [Related]  

  • 2. [Beta-receptor blockers in ischemic heart disease: the pathophysiological and clinical aspects].
    Urbaszek W; Modersohn D
    Z Arztl Fortbild (Jena); 1979 Feb; 73(3):101-6. PubMed ID: 34938
    [No Abstract]   [Full Text] [Related]  

  • 3. Beta-adrenoceptor blockade and intrinsic sympathomimetic activity--relevance in the treatment of ischaemic heart disease.
    Northcote RJ; Ballantyne D
    Scott Med J; 1985 Oct; 30(4):208-15. PubMed ID: 2869581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Digitalis and coronary heart disease (author's transl)].
    Schüren KP; Kötter V; Schröder R
    Z Kardiol; 1980 May; 69(5):319-28. PubMed ID: 6109408
    [No Abstract]   [Full Text] [Related]  

  • 5. [Intrinsic sympathomimetic activity of adrenergic beta receptor blockaders and its role in various clinical situations].
    Bubiński R
    Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1713-6. PubMed ID: 6151656
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined therapy with beta-adrenergic blockers and calcium-antagonists in patients with ischemic heart disease.
    Winniford MD; Hillis LD
    Herz; 1982 Aug; 7(4):243-9. PubMed ID: 6127300
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effects of nitroglycerin on exercise hemodynamics in patients with coronary heart disease under treatment with beta-blockers (mepindolol, oxprenolol) and a calcium-antagonist (fendiline) (author's transl)].
    Reiterer W
    Wien Med Wochenschr; 1980 Dec; 130(23):772-7. PubMed ID: 6111161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Some advances in cardiovascular pharmacology (author's transl)].
    Ding GS
    Sheng Li Ke Xue Jin Zhan; 1981 Feb; 12(2):97-103. PubMed ID: 6118953
    [No Abstract]   [Full Text] [Related]  

  • 9. [Recent acquisitions on beta blocking agents].
    Lesbre JP; Mériel P; Baledent M
    Therapeutique; 1971 Nov; 47(9):797-9. PubMed ID: 4401847
    [No Abstract]   [Full Text] [Related]  

  • 10. [The role of the sympathomimetic activity of beta-adrenergic blockaders in the treatment of patients with chronic ischemic heart disease].
    Ol'binskaia LI; Bragina GI
    Ter Arkh; 1983; 55(9):35-40. PubMed ID: 6138864
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of different groups of adrenergic beta receptor blockaders on the clinical course of the disease, work capacity and echocardiographic indicators in ischemic heart disease].
    Komarov FI; Ol'binskaia LI; Bragina GI
    Ter Arkh; 1979; 51(8):13-7. PubMed ID: 41333
    [No Abstract]   [Full Text] [Related]  

  • 12. Anesthetic management problems posed by therapeutic advances: 3. Beta-adrenergic blocking drugs.
    Merin RG
    Anesth Analg; 1972; 51(4):617-24. PubMed ID: 4402735
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of beta-adrenoceptor antagonists with and without intrinsic sympathomimetic activity on local wall motion abnormalities in patients with coronary heart disease.
    Gleichmann U; Fassbender D; Trieb G; Mannebach H; Ohlmeier H
    Br J Clin Pharmacol; 1982; 13(Suppl 2):301S-304S. PubMed ID: 6125180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B
    Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of beta-blockers: classical aspects and recent developments.
    Haeusler G
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S1-9. PubMed ID: 11527109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy with beta-blocking-agents (author's transl)].
    Bolte HD
    MMW Munch Med Wochenschr; 1978 Nov; 120(44):1461-6. PubMed ID: 30043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The beta 2-pseudoselectivity of ISA (intrinsic sympathomimetic action)--consequences for differential therapy with beta-blockers with and without ISA?].
    Werdan K; Reithmann C
    Dtsch Med Wochenschr; 1988 Feb; 113(7):272-4. PubMed ID: 2893724
    [No Abstract]   [Full Text] [Related]  

  • 18. [Intrinsic sympathicomimetic activity of beta blockers].
    Beckers J
    Rev Med Liege; 1988 Oct; 43(19):613-22. PubMed ID: 2903532
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of cardioselectivity and intrinsic sympathomimetic activity in beta-blocking drugs in chronic coronary artery disease.
    DiBianco R
    Am J Cardiol; 1987 May; 59(13):38F-43F. PubMed ID: 2883877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [15 years of therapy with beta-receptor blockers. Tendency for differentiation].
    Kersting F; Kasper W; Meinertz T
    Med Klin; 1979 Aug; 74(32-33):1179-88. PubMed ID: 38385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.